Trial Profile
Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms GEP14-LEECAP
- 06 Dec 2023 Status changed from active, no longer recruiting to completed.
- 08 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 08 Mar 2022 Status changed from recruiting to active, no longer recruiting.